KR20080090538A - 케모킨 수용체 활성 조절인자로서의 피페라지닐 유도체 - Google Patents
케모킨 수용체 활성 조절인자로서의 피페라지닐 유도체 Download PDFInfo
- Publication number
- KR20080090538A KR20080090538A KR1020087020838A KR20087020838A KR20080090538A KR 20080090538 A KR20080090538 A KR 20080090538A KR 1020087020838 A KR1020087020838 A KR 1020087020838A KR 20087020838 A KR20087020838 A KR 20087020838A KR 20080090538 A KR20080090538 A KR 20080090538A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- heteroaryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000009410 Chemokine receptor Human genes 0.000 title description 8
- 108050000299 Chemokine receptor Proteins 0.000 title description 8
- 230000000694 effects Effects 0.000 title description 6
- 125000004193 piperazinyl group Chemical group 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 20
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 13
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 11
- 208000026935 allergic disease Diseases 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 208000006673 asthma Diseases 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 646
- 125000003118 aryl group Chemical group 0.000 claims description 634
- 125000000623 heterocyclic group Chemical group 0.000 claims description 571
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 534
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 499
- 125000001072 heteroaryl group Chemical group 0.000 claims description 484
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 481
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 390
- 125000005843 halogen group Chemical group 0.000 claims description 341
- 239000001257 hydrogen Substances 0.000 claims description 317
- 229910052739 hydrogen Inorganic materials 0.000 claims description 317
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 312
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 288
- 125000004104 aryloxy group Chemical group 0.000 claims description 242
- 125000003342 alkenyl group Chemical group 0.000 claims description 197
- 125000000304 alkynyl group Chemical group 0.000 claims description 195
- 125000001188 haloalkyl group Chemical group 0.000 claims description 195
- 125000005842 heteroatom Chemical group 0.000 claims description 111
- 229910052760 oxygen Inorganic materials 0.000 claims description 105
- 229910052717 sulfur Inorganic materials 0.000 claims description 105
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 85
- 150000001875 compounds Chemical class 0.000 claims description 75
- -1 heteroaryl-Al Chemical group 0.000 claims description 49
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 48
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims 66
- 206010001889 Alveolitis Diseases 0.000 claims 5
- 206010002329 Aneurysm Diseases 0.000 claims 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 5
- 208000011231 Crohn disease Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 5
- 208000037357 HIV infectious disease Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 5
- 206010020751 Hypersensitivity Diseases 0.000 claims 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 5
- 208000001132 Osteoporosis Diseases 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 5
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 5
- 206010037660 Pyrexia Diseases 0.000 claims 5
- 206010038389 Renal cancer Diseases 0.000 claims 5
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 206010038923 Retinopathy Diseases 0.000 claims 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 5
- 230000007815 allergy Effects 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 5
- 206010009887 colitis Diseases 0.000 claims 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims 5
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 5
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 5
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 5
- 201000010982 kidney cancer Diseases 0.000 claims 5
- 201000008383 nephritis Diseases 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 201000008482 osteoarthritis Diseases 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 5
- 230000003589 nefrotoxic effect Effects 0.000 claims 4
- 231100000381 nephrotoxic Toxicity 0.000 claims 4
- 201000002793 renal fibrosis Diseases 0.000 claims 4
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 230000002988 nephrogenic effect Effects 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 abstract description 26
- 108700012434 CCL3 Proteins 0.000 abstract description 25
- 208000027866 inflammatory disease Diseases 0.000 abstract description 6
- 230000001363 autoimmune Effects 0.000 abstract description 2
- 230000007170 pathology Effects 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 166
- 108010055166 Chemokine CCL5 Proteins 0.000 description 10
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 102000019034 Chemokines Human genes 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 8
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 7
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 5
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000002932 luster Substances 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 4
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 4
- 102000001902 CC Chemokines Human genes 0.000 description 4
- 108010040471 CC Chemokines Proteins 0.000 description 4
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- 230000003399 chemotactic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 3
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 3
- 108010017319 CCR1 Receptors Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108050005711 C Chemokine Proteins 0.000 description 2
- 102000017483 C chemokine Human genes 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102000004500 CCR1 Receptors Human genes 0.000 description 2
- 108050006947 CXC Chemokine Proteins 0.000 description 2
- 102000019388 CXC chemokine Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 101000978374 Mus musculus C-C motif chemokine 12 Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QUPFKBITVLIQNA-KPKJPENVSA-N (5e)-2-sulfanylidene-5-[[5-[3-(trifluoromethyl)phenyl]furan-2-yl]methylidene]-1,3-thiazolidin-4-one Chemical compound FC(F)(F)C1=CC=CC(C=2OC(\C=C\3C(NC(=S)S/3)=O)=CC=2)=C1 QUPFKBITVLIQNA-KPKJPENVSA-N 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 102100034065 Atypical chemokine receptor 4 Human genes 0.000 description 1
- 108700036632 Atypical chemokine receptor 4 Proteins 0.000 description 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
- 102100031174 C-C chemokine receptor type 10 Human genes 0.000 description 1
- 101710109563 C-C chemokine receptor type 10 Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 1
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 1
- 101710149871 C-C chemokine receptor type 6 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 101710149858 C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101710149872 C-C chemokine receptor type 8 Proteins 0.000 description 1
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 1
- 102100023705 C-C motif chemokine 14 Human genes 0.000 description 1
- 102100023700 C-C motif chemokine 16 Human genes 0.000 description 1
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 102100036849 C-C motif chemokine 24 Human genes 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 102000018211 CC chemokine receptor 1 Human genes 0.000 description 1
- 108010039171 CC cytokine receptor-4 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 108010083647 Chemokine CCL24 Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- 101000728693 Homo sapiens 28S ribosomal protein S11, mitochondrial Proteins 0.000 description 1
- 101000980744 Homo sapiens C-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000946926 Homo sapiens C-C chemokine receptor type 5 Proteins 0.000 description 1
- 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 1
- 101000978375 Homo sapiens C-C motif chemokine 16 Proteins 0.000 description 1
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 101100490183 Mus musculus Ackr4 gene Proteins 0.000 description 1
- 101000974353 Mus musculus Nuclear receptor coactivator 5 Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76305106P | 2006-01-27 | 2006-01-27 | |
| US60/763,051 | 2006-01-27 | ||
| US11/625,889 | 2007-01-23 | ||
| US11/625,889 US7615556B2 (en) | 2006-01-27 | 2007-01-23 | Piperazinyl derivatives as modulators of chemokine receptor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080090538A true KR20080090538A (ko) | 2008-10-08 |
Family
ID=37969746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087020838A Withdrawn KR20080090538A (ko) | 2006-01-27 | 2007-01-25 | 케모킨 수용체 활성 조절인자로서의 피페라지닐 유도체 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7615556B2 (enExample) |
| EP (1) | EP1973880B1 (enExample) |
| JP (1) | JP2009524691A (enExample) |
| KR (1) | KR20080090538A (enExample) |
| AU (1) | AU2007208031A1 (enExample) |
| NO (1) | NO20083358L (enExample) |
| WO (1) | WO2007087585A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180131520A (ko) * | 2011-12-08 | 2018-12-10 | 삼성전자주식회사 | 광굴절 복합체, 상기 광굴절 복합체를 포함하는 공간광 변조기 및 홀로그램 디스플레이 장치 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067237B2 (en) | 2005-12-13 | 2011-11-29 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| CN101808991A (zh) * | 2007-07-24 | 2010-08-18 | 百时美施贵宝公司 | 作为趋化因子受体活性调节剂的哌啶基衍生物 |
| JP5292400B2 (ja) * | 2007-07-24 | 2013-09-18 | ブリストル−マイヤーズ スクイブ カンパニー | ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体 |
| EP2254602B1 (en) | 2008-02-13 | 2018-11-21 | President and Fellows of Harvard College | Continuous cell programming devices |
| US8492550B2 (en) | 2008-03-07 | 2013-07-23 | Bristol-Myers Squibb Company | Hydroxyalkanyl amides as modulators of chemokine receptor activity |
| KR101672884B1 (ko) * | 2008-03-19 | 2016-11-04 | 오림드 파마, 인코포레이티드 | 중추신경계 질환 및 질병 치료에 유효한 신규 화합물 |
| US20210130285A1 (en) | 2008-03-19 | 2021-05-06 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| US10793515B2 (en) | 2008-03-19 | 2020-10-06 | Aurimmed Pharma, Inc. | Compounds advantageous in the treatment of central nervous system diseases and disorders |
| TWI433838B (zh) | 2008-06-25 | 2014-04-11 | 必治妥美雅史谷比公司 | 作為趨化因子受體活性調節劑之六氫吡啶衍生物 |
| WO2011014871A1 (en) * | 2009-07-31 | 2011-02-03 | President And Fellows Of Harvard College | Programming of cells for tolerogenic therapies |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| CA2813751C (en) | 2010-10-06 | 2019-11-12 | President And Fellows Of Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
| CN107137357B (zh) | 2012-04-16 | 2020-11-24 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| US8716235B2 (en) | 2012-04-18 | 2014-05-06 | Albert Einstein College Of Medicine Of Yeshiva University | Method for inhibiting metastasis by using anti-CCL3 antibodies |
| WO2015046595A1 (ja) * | 2013-09-30 | 2015-04-02 | 国立大学法人東京大学 | アディポネクチン受容体活性化化合物 |
| US10682400B2 (en) | 2014-04-30 | 2020-06-16 | President And Fellows Of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| EP3280464A4 (en) | 2015-04-10 | 2018-09-26 | President and Fellows of Harvard College | Immune cell trapping devices and methods for making and using the same |
| CN115487351A (zh) | 2016-02-06 | 2022-12-20 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
| DK3484448T3 (da) | 2016-07-13 | 2025-06-10 | Harvard College | Antigenpræsenterende cellemimetiske stilladser og fremgangsmåder til fremstilling og brug af disse |
| JP7274214B2 (ja) | 2016-08-02 | 2023-05-16 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫応答を調節するための生体材料 |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9104656D0 (en) | 1991-03-05 | 1991-04-17 | Zambeletti Spa L | Pharmaceuticals |
| DE4243858A1 (de) | 1992-12-23 | 1994-06-30 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5459151A (en) | 1993-04-30 | 1995-10-17 | American Home Products Corporation | N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents |
| US5777112A (en) | 1994-06-13 | 1998-07-07 | Merck & Co., Inc | Piperazine compounds promote release of growth hormone |
| WO1997003060A1 (en) * | 1995-07-13 | 1997-01-30 | Senju Pharmaceutical Co., Ltd. | Piperazine derivatives and use of the same |
| FR2740134B1 (fr) * | 1995-10-18 | 1998-01-09 | Pf Medicament | Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant |
| DE69628050T2 (de) * | 1995-10-25 | 2004-04-01 | Senju Pharmaceutical Co., Ltd. | Angiogenese Hemmer |
| WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU4722197A (en) | 1996-10-22 | 1998-05-15 | Daiichi Pharmaceutical Co., Ltd. | Novel remedies for infectious diseases |
| US5847148A (en) | 1997-04-10 | 1998-12-08 | Pharmacia & Upjohn Company | Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| DE69819349T2 (de) * | 1997-08-29 | 2004-07-22 | Tularik Ltd. | 1-amino-7-isochinolin-derivate als serin protease inhibitoren |
| CN1305473A (zh) * | 1998-04-16 | 2001-07-25 | 得克萨斯生物技术公司 | 抑制整联蛋白与其受体结合的n,n－二取代的酰胺 |
| US6391865B1 (en) | 1999-05-04 | 2002-05-21 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
| JP2003505435A (ja) | 1999-06-04 | 2003-02-12 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体ゴニストとしての置換ピペリジン |
| DE10041402A1 (de) * | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| DE19939910A1 (de) | 1999-08-23 | 2001-03-01 | Morphochem Ag | Neue Verbindungen, die Tryptase-Aktivität hemmen |
| AUPQ386899A0 (en) * | 1999-11-04 | 1999-11-25 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds |
| JP2001354657A (ja) | 2000-06-09 | 2001-12-25 | Sds Biotech:Kk | 置換ピペラジン誘導体及び農園芸用殺菌剤 |
| DE10056312A1 (de) * | 2000-11-14 | 2002-05-16 | Bayer Ag | Substituierte Amidoalkyluracile und ihre Verwendung |
| US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| ATE411021T1 (de) | 2001-07-18 | 2008-10-15 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin- rezeptor-agonisten |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| WO2003022835A1 (en) | 2001-09-06 | 2003-03-20 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| MXPA04005158A (es) * | 2001-11-30 | 2004-08-11 | Schering Corp | Antagonistas receptores de adenosina a2a biciclica de (1.2.4]- triazol. |
| ATE458483T1 (de) | 2001-12-20 | 2010-03-15 | Osi Pharm Inc | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung |
| DE60236458D1 (de) | 2001-12-20 | 2010-07-01 | Osi Pharm Inc | Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung |
| US7041681B2 (en) | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| GB0224917D0 (en) | 2002-10-25 | 2002-12-04 | Novartis Ag | Organic compounds |
| CA2512886A1 (en) | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| WO2004113323A1 (en) | 2003-06-13 | 2004-12-29 | Schering Aktiengesellschaft | Quinolyl amide derivatives as ccr-5 antagonists |
| GB0315203D0 (en) | 2003-06-28 | 2003-08-06 | Celltech R&D Ltd | Chemical compounds |
| CN1942186B (zh) * | 2004-03-09 | 2010-10-06 | 国家卫生研究院 | 吡咯烷化合物 |
| GB0412468D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| US7723360B2 (en) | 2004-08-06 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Alkyl-and piperidine-substituted benzimidazole derivatives |
-
2007
- 2007-01-23 US US11/625,889 patent/US7615556B2/en active Active
- 2007-01-25 JP JP2008552564A patent/JP2009524691A/ja not_active Withdrawn
- 2007-01-25 AU AU2007208031A patent/AU2007208031A1/en not_active Abandoned
- 2007-01-25 KR KR1020087020838A patent/KR20080090538A/ko not_active Withdrawn
- 2007-01-25 EP EP07710312.5A patent/EP1973880B1/en active Active
- 2007-01-25 WO PCT/US2007/061014 patent/WO2007087585A1/en not_active Ceased
-
2008
- 2008-07-31 NO NO20083358A patent/NO20083358L/no not_active Application Discontinuation
-
2009
- 2009-08-05 US US12/536,070 patent/US8609664B2/en active Active - Reinstated
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180131520A (ko) * | 2011-12-08 | 2018-12-10 | 삼성전자주식회사 | 광굴절 복합체, 상기 광굴절 복합체를 포함하는 공간광 변조기 및 홀로그램 디스플레이 장치 |
| KR20180131519A (ko) * | 2011-12-08 | 2018-12-10 | 삼성전자주식회사 | 광굴절 복합체, 상기 광굴절 복합체를 포함하는 공간광 변조기 및 홀로그램 디스플레이 장치 |
Also Published As
| Publication number | Publication date |
|---|---|
| US8609664B2 (en) | 2013-12-17 |
| EP1973880A1 (en) | 2008-10-01 |
| JP2009524691A (ja) | 2009-07-02 |
| WO2007087585A1 (en) | 2007-08-02 |
| US7615556B2 (en) | 2009-11-10 |
| EP1973880B1 (en) | 2013-08-07 |
| US20090298845A1 (en) | 2009-12-03 |
| US20070179148A1 (en) | 2007-08-02 |
| AU2007208031A1 (en) | 2007-08-02 |
| NO20083358L (no) | 2008-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7615556B2 (en) | Piperazinyl derivatives as modulators of chemokine receptor activity | |
| KR101348491B1 (ko) | 케모킨 수용체 활성의 조절인자로서의 피페리디닐 유도체 | |
| US9040526B2 (en) | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity | |
| US8501782B2 (en) | Piperidinyl derivatives as modulators of chemokine receptor activity | |
| US8536198B2 (en) | Piperidine derivatives as modulators of chemokine receptor activity | |
| US7381738B2 (en) | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | |
| US8492550B2 (en) | Hydroxyalkanyl amides as modulators of chemokine receptor activity | |
| US20050192276A1 (en) | Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity | |
| US8324251B2 (en) | Cyclic modulators of chemokine receptor activity | |
| MX2008009287A (en) | Piperazinyl derivatives as modulators of chemokine receptor activity | |
| CN101410376A (zh) | 作为趋化因子受体活性调节剂的哌嗪基衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080826 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |